Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q4 revenue rises 7.7% to $536.6 million; diluted EPS $3.67 vs. $2.46

Positive Impact 4 of 5 earnings Written later

Medpace reported fourth-quarter 2024 revenue of $536.6 million, up 7.7%, and GAAP diluted earnings of $3.67 per share, up from $2.46 a year earlier. The board also approved a $600 million increase to the stock repurchase program, and the company forecast 2025 revenue of $2.110 billion to $2.210 billion, growth of 0.0% to 4.8%, for shareholders to weigh against slower new business awards.

Key points

  • Q4 2024 revenue was $536.6 million, up 7.7% from $498.4 million; GAAP net income was $117.0 million.
  • Q4 2024 net new business awards fell 13.8% to $529.7 million, for a net book-to-bill ratio of 0.99x.
  • 2025 guidance: revenue of $2.110 billion to $2.210 billion and GAAP diluted EPS of $11.93 to $12.69.
  • On February 6, 2025, the board approved a $600 million increase to the stock repurchase program.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECFeb 10, 2025, 4:15 PM ET
Accession number0001668397-25-000012

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.